CareDx, Inc (NASDAQ:CDNA) Shares Purchased by Man Group plc

Man Group plc raised its position in CareDx, Inc (NASDAQ:CDNA - Free Report) by 186.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 69,185 shares of the company's stock after purchasing an additional 45,054 shares during the period. Man Group plc owned 0.13% of CareDx worth $1,481,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the company. Thompson Davis & CO. Inc. increased its position in shares of CareDx by 6.3% in the 4th quarter. Thompson Davis & CO. Inc. now owns 16,050 shares of the company's stock valued at $344,000 after purchasing an additional 950 shares during the last quarter. Hsbc Holdings PLC grew its position in CareDx by 6.9% during the 4th quarter. Hsbc Holdings PLC now owns 17,131 shares of the company's stock worth $365,000 after purchasing an additional 1,109 shares during the last quarter. Legal & General Group Plc grew its position in CareDx by 1.3% during the 4th quarter. Legal & General Group Plc now owns 89,751 shares of the company's stock worth $1,922,000 after purchasing an additional 1,118 shares during the last quarter. Sterling Capital Management LLC grew its position in CareDx by 771.2% during the 4th quarter. Sterling Capital Management LLC now owns 1,272 shares of the company's stock worth $27,000 after purchasing an additional 1,126 shares during the last quarter. Finally, Principal Financial Group Inc. grew its position in CareDx by 6.5% during the 4th quarter. Principal Financial Group Inc. now owns 18,984 shares of the company's stock worth $406,000 after purchasing an additional 1,151 shares during the last quarter.

Insider Transactions at CareDx

In related news, Director Christine Cournoyer sold 16,700 shares of the business's stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $14.13, for a total value of $235,971.00. Following the completion of the sale, the director now directly owns 37,045 shares in the company, valued at approximately $523,445.85. The trade was a 31.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Peter Maag sold 13,281 shares of the business's stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $17.23, for a total transaction of $228,831.63. Following the completion of the sale, the director now owns 316,743 shares of the company's stock, valued at approximately $5,457,481.89. The trade was a 4.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 59,382 shares of company stock worth $934,509 over the last ninety days. 4.90% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have issued reports on CDNA. HC Wainwright reissued a "neutral" rating and set a $25.00 price objective on shares of CareDx in a research report on Monday, May 5th. Stephens restated an "overweight" rating and set a $40.00 target price on shares of CareDx in a research report on Monday, May 5th. Wall Street Zen cut shares of CareDx from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Finally, The Goldman Sachs Group cut their target price on shares of CareDx from $34.00 to $26.00 and set a "buy" rating for the company in a research report on Thursday, April 17th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $30.33.

CareDx Trading Up 4.0%

Shares of NASDAQ CDNA traded up $0.68 during midday trading on Tuesday, reaching $17.63. 1,378,386 shares of the stock were exchanged, compared to its average volume of 896,883. The company has a market capitalization of $981.66 million, a P/E ratio of -6.53 and a beta of 2.27. CareDx, Inc has a 52-week low of $12.90 and a 52-week high of $34.84. The stock has a 50 day moving average price of $17.44 and a 200-day moving average price of $20.66.

CareDx (NASDAQ:CDNA - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The company reported $0.09 EPS for the quarter, topping analysts' consensus estimates of $0.06 by $0.03. The business had revenue of $84.69 million during the quarter, compared to the consensus estimate of $84.56 million. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The company's quarterly revenue was up 17.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.03) earnings per share. On average, analysts forecast that CareDx, Inc will post -0.9 earnings per share for the current year.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.